Platelets and Vascular Thrombosis
- 7 April 1994
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 330 (14) , 1006-1007
- https://doi.org/10.1056/nejm199404073301411
Abstract
Heart attacks and strokes are usually caused by thrombo-occlusive events at sites of atherosclerotic stenosis and plaque rupture1. These thrombotic processes are generally mediated by thrombin, dependent on the action of platelets, and not completely responsive to conventional therapy with aspirin and heparin2,3. Resistant thrombi may also form after vascular procedures commonly performed for the treatment of symptomatic atherosclerotic disease, including coronary angioplasty, various types of atherectomy, placement of endovascular stents, endarterectomy, and implantation of small-caliber vascular grafts4,5. In fact, abrupt vessel closure and coronary restenosis are the two most difficult problems limiting the success . . .Keywords
This publication has 13 references indexed in Scilit:
- Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary AngioplastyNew England Journal of Medicine, 1994
- Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group.Circulation, 1994
- Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patientsBMJ, 1994
- Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein llb/llla in patients undergoing elective coronary angioplastyCoronary Artery Disease, 1993
- Abrupt vessel closure complicating coronary angioplasty: Clinical, angiographic and therapeutic profileJournal of the American College of Cardiology, 1992
- GPIIb-IIIa: The responsive integrinCell, 1991
- Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.Journal of Clinical Investigation, 1990
- Platelets and Thrombolytic TherapyNew England Journal of Medicine, 1990
- Effects of monoclonal antibodies against the platelet glycoprotein IIb/IIIa complex on thrombosis and hemostasis in the baboon.Journal of Clinical Investigation, 1988
- A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa.Journal of Clinical Investigation, 1983